Alterations in tumor necrosis factor-induced endothelial cell procoagulant activity by hyperthermia

International Journal of Cancer

Volumn 111, Issue 3, 2004, Pages 457-462

  Carroll, Nancy M ^a   Elaraj, Dina M ^a   Puhlmann, Markus ^a   Weinreich, David M ^a   Turner, Ewa M ^a   Xu, Hui ^a   Alexander Jr , H Richard ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Coagulation; Endothelium; Hyperthermia; Isolated limb perfusion; Tissue factor; Tissue factor pathway inhibitor 2; Tumor necrosis factor

Indexed keywords

MESSENGER RNA; PLACENTA PROTEIN 5; PROCOAGULANT; THROMBOPLASTIN; TUMOR NECROSIS FACTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD CLOTTING; CELL VIABILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; HUMAN; HUMAN CELL; HYPERTHERMIC THERAPY; IMMUNE RESPONSE; IN VITRO STUDY; INFLAMMATION; LIMB PERFUSION; MELANOMA; PRIORITY JOURNAL; REGIONAL PERFUSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMA; TEMPERATURE DEPENDENCE; TUMOR VASCULARIZATION; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

BLOOD COAGULATION FACTORS; CELL LINE; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; GLYCOPROTEINS; HEAT; HUMANS; HYPERTHERMIA, INDUCED; KINETICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THROMBOPLASTIN; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA; UMBILICAL VEINS;

EID: 3242881278     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20272     Document Type: Article

References (39)

1. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-70.
2. Alexander HR, Feldman AL. Tumor necrosis factor: basic principles and clinical application in systemic and regional cancer treatment. In: Steven MD, Rosenberg A, eds. Biologic therapy of cancer. Philadelphia: Lippincott, 2000. 174-93.
3. Alexander HR Jr. Isolation perfusion. In: DeVita Jr VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. Philadelphia: Lippincott Williams & Wilkins, 2001. 769-76.
4. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52-60.
5. Lienard D, Eggermont AMM, Schraffordt-Koops H, Kroon B, Towse G, Hiemstra S, Schmilz P, Clarke J, Steinmann G, Rosenkaimer F, Lejeune FJ. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999;9:491-502.
6. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor. Cancer J Sci Am 1995;1:122-30.
7. Bartlett DL, Ma G, Alexander HR, Libutti SK, Fraker DL. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer 1997;80:2084-90.
8. Eggermont AMM, Koops HS, Klausner JM, Kroon BBR, Schlag PM, Liénard DVGAN, Hoekstra HJ, Meller I, Nieweg OE, Kettelhack C, Ben-Ari G, Pector J-C, Lejeune FJ. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. Ann Surg 1996;224: 756-65.
9. Michie HR, Manogue KR, Springgs DR, Revhaug A, O'Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988;318:1481-6.
10. Renard N, Liénard D, Lespagnard L, Eggermont A, Heimann R, Lejeune F. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNFα). Int J Cancer 1994;57:656-63.
11. Gutman M, Inbar M, Lev-Shlush D, Abu-Abid S, Mozes M, Chaitchik S, Meller I, Klausner JM. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer 1997;79:1129-37.
12. Eggermont AMM, Koops HS, Liénard D, Kroon BBR, Van Geel AN, Hoekstra HJ. Isolated limb perfusion with high dose tumor necrosis factor-α in combination with interferon-gamma and melphalan for irresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996;14:2653-65.
13. Wu PC, Alexander HR, Huang J, Hwu P, Gnant M, Berger AC, Turner E, Wilson O, Libutti SK. In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-α is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII). Cancer Res 1999;59:205-12.
14. Olieman AFT, Van Ginkel RJ, Hoekstra HJ, Mooyaart EL, Molenaar WM, Koops HS. Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Ann Surg Oncol 1997;4:64-9.
15. Posner M, Lienard D, Lejeune F, Rosenfelder D, Kirkwood J. Hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor (TNF) alone for metastatic intransit melanoma [abstract]. American Society of Clinical Oncology 1994;13:396.
16. Nooijen P, Manusama ER, Eggermont AM, Schalkwijk L, Stavast J, Marquet RL, De Waal RM, Ruiter DJ. Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br J Cancer 1996;74:1908-15.
17. Morrissey JH, Fakhrai H, Edgington TS. Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade. Cell 1987;50:129-35.
18. Nemerson Y. Tissue factor and hemostasis. Blood 1988;71:1-8.
19. Osterud B, Bajaj M, Bajaj S. Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. Thromb Haemost 1995;73:873-5.
20. Mirshahi F, Vasse M, Tedgui A, Li H, Merval R, Legrand E, Vannier JP, Soria J, Soria C. Oncostatin M induces procoagulant activity in human vascular smooth muscle cells by modulating the balance between tissue factor and tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 2002;13:449-55.
21. Lanir N, Aharon A, Brenner B. Procoagulant and anticoagulant mechanisms in human placenta. Semin Thromb Hemost 2003;29:175-83.
22. Sprecher CA, Kisiel W, Mathewes S, Foster DC. Molecular cloning, expression, and partial characterization of a second human tissue factor pathway inhibitor. Proc Natl Acad Sci USA 1994;91:3353-7.
23. Iochmann S, Reverdiau-Moalic P, Hube F, Bardos P, Gruel Y. Demonstration of inducible TFPI-2 mRNA synthesis in BeWo and JEG-3 trophoblast cells using a competitive RT-PCR. Thromb Res 2002;105: 217-23.
24. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996;6:986-94.
25. Peng R, Bongard FS. Hypothermia in trauma patients. J Am Coll Surg 1999;188:685-96.
26. Gnant M, Turner EM, Alexander HR. Effects of hyperthermia and tumour necrosis factor on inflammatory cytokine secretion and procoagulant activity in endothelial cells. Cytokine 2000;12:339-47.
27. Ameri A, Kuppuswamy M, Basu S, Bajaj S. Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood 1992;79:3219-26.
28. Bajaj M, Bajaj S. Tissue factor pathway inhibitor: potential therapeutic applications. Thromb Haemost 1997;78:471-7.
29. Hasday JD, Bannerman D, Sakarya S, Cross AS, Singh IS, Howard D, Drysdale BE, Goldblum SE. Exposure to febrile temperature modifies endothelial cell response to tumor necrosis factor-alpha. J Appl Physiol 2001;90:90-8.
30. Bierhaus A, Zhang Y, Deng Y, Mackman N, Quehenberger P, Haase M, Luther T, Muller M, Bohrer H, Greten J, Martin E, Bacuerle P, et al. Mechanism of the tumor necrosis factor alpha-mediated induction of endothelial tissue factor. J Biol Chem 1995;270:26419-32.
31. Frossard J, Pastor CM, Hadengue A. Effect of hyperthermia on NF-κB binding activity in cerulein-induced pancreatitis. Am J Physiol Gastrointest Liver Physiol 2001;280:G1157-62.
32. Hube F, Reverdiau P, Iochmann S, Cherpi-Antar C, Gruel Y. Characterization and functional analysis of TFPI-2 gene promoter in a human choriocarcinoma cell line. Thromb Res 2003;109:207-15.
33. Basi DL, Ross KF, Hodges JS, Herzberg MC. The modulation of tissue factor by endothelial cells during heat shock. J Biol Chem 2003;278:11065-71.
34. Fraker DL, Alexander HR, Thom AK. Use of tumor necrosis factor in isolated hepatic perfusion. Circ Shock 1994;44:45-50.
35. Hendriks JM, Van Schil PE. Isolated lung perfusion for the treatment of pulmonary metastases. Surg Oncol 1998;7:59-63.
36. Walther MM, Jennings SB, Choyke PL, Andrich M, Hurley K, Linehan WM, Rosenberg SA, Alexander RB. Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma. World J Urol 1996;14:S2-7.
37. Vrouenraets BC, Klaase JM, Nieweg OE, Kroon BBR. Toxicity and morbidity of isolated limb perfusion. Semin Surg Oncol 1998;14 :224-31.
38. Vrouenraets BC, Eggermont AM, Hart AA, Klaase JM, Van Geel AN, Nieweg OE, Kroon BB. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor-alpha vs. toxicity after melphalan alone. Eur J Surg Oncol 2001;27:390-5.
39. Renard N, Nooijen PT, Schalkwijk L, De Waal RM, Eggermont AM, Lienard D, Kroon BB, Lejeune FJ, Ruiter DJ. VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha. J Pathol 1995;176:279-87.